Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
2 MAY 2023 at 16.15 EEST
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 1 May 2023 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
| % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % (points A + B) | Total number of shares and voting rights of issuer |
Resulting situation on the date on which threshold was crossed or reached | 4.94% shares | 0.09% shares | 5.03% shares | 141,134,278 shares |
Position of previous notification (if applicable) | Below 5% shares | Below 5% shares | Below 5% shares |
|
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
Class/type of shares | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) |
FI0009014377 |
| 6,972,993 shares |
| 4.94% shares |
POINT A SUBTOTAL | 6,972,993 shares | 4.94% shares | ||
Point B: Financial instruments according to SMA 9:6a:
Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
Securities Lent | N/A | N/A | Physical | 133,020 shares | 0.09% shares |
CFD | N/A | N/A | Cash | 5,725 shares | 0.00% shares |
|
|
| POINT B SUBTOTAL | 138,745 shares | 0.09% shares |
Orion Corporation
Liisa Hurme |
| Olli Huotari |
|
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
